Journal: Materials Today Bio

Article Title: Microcarriers encapsulating COL1A1 mRNA-loaded nanovesicles for skin photoaging treatment

doi: 10.1016/j.mtbio.2026.103126

Figure Lengend Snippet: Scheme of the fabrication of the microcarriers and delivery of engineered nanovesicles for photoaging therapy. Abbreviations: HDF, human dermal fibroblast; Exos, exosomes; Emvs, engineered nanovesicles; HDF COL1A1 Emvs, Emvs derived from HDFs transfected with COL1A1 plasmid (COL1A1 mRNA–encapsulating nanovesicles); ROS, reactive oxygen species; COL1A1, collagen type I alpha 1 chain.

Article Snippet: The concentration of human type I procollagen was measured using a human type I procollagen ELISA kit (Elabscience Biotechnology, China) according to the manufacturer's instructions.

Techniques: Derivative Assay, Transfection, Plasmid Preparation

Journal: Materials Today Bio

Article Title: Microcarriers encapsulating COL1A1 mRNA-loaded nanovesicles for skin photoaging treatment

doi: 10.1016/j.mtbio.2026.103126

Figure Lengend Snippet: In vivo biosafety evaluation. a) In vivo imaging of subcutaneous injection sites across different groups. b) Quantification of relative fluorescence intensity (n = 5). c) Histological analysis via H&E staining of the heart, liver, spleen, lung, and kidney tissues. d) ELISA quantification of IL-6 levels and TNF-α levels (n = 5). e) Quantification of ALT, AST, CREA, and UA levels (n = 3). The scale bar is 300 μm in c).

Article Snippet: The concentration of human type I procollagen was measured using a human type I procollagen ELISA kit (Elabscience Biotechnology, China) according to the manufacturer's instructions.

Techniques: In Vivo, In Vivo Imaging, Injection, Fluorescence, Staining, Enzyme-linked Immunosorbent Assay

Journal: Journal of the Endocrine Society

Article Title: Subclinically low BMD in young men is associated with compromised bone microarchitecture and lower lean mass

doi: 10.1210/jendso/bvag003

Figure Lengend Snippet: Biomarkers. Fig. 1 depicts all assessed biomarker concentrations. The total hip, femoral neck, or lumbar spine (Lower) group is depicted in black filled circles, while the control (Con) group is in clear squares. A, P1NP (pg/mL); B, alkaline phosphatase (ALP) (pg/mL); C, tartrate-resistant acid phosphatase 5b (TRAP5b) (U/L); D, sclerostin (pmol/L); E, β C-terminal cross-linked telopeptide of type I collagen (βCTX) (pmol/L); F, testosterone (ng/mL); G, estradiol (pg/mL); H, parathyroid hormone (PTH) (pg/mL); I, insulin-like growth factor-1 (IGF-1) (ng/mL); J, insulin-like growth factor-1 binding protein 5 (IGFBP-5) (ng/mL).

Article Snippet: Commercially available enzyme-linked immunosorbent assays were used to determine circulating concentrations of serum procollagen type I N-terminal propeptide (PINP; Novus catalog No. NBP2-76465, RRID:AB_3720306, 1:200 dilution, CV 5.3%, sensitivity 9.4 pg/mL), alkaline phosphatase (ALP; Novus catalog No. NBP2-68197, RRID:AB_3720307, CV 6.0%, sensitivity 46.9 pg/mL), tartrate-resistant acid phosphatase 5b (TRAP5b; Immunodiagnostic Systems catalog No. SB-TR201A, RRID:AB_3095995, CV 4.7%, sensitivity 0.4 U/L), sclerostin (Biomedica catalog No. BI-20492, RRID:AB_2894889, CV 6.4%, sensitivity 3.2 pmol/L), testosterone (Alpco Diagnostics catalog No. 11-TESHU-E01, RRID:AB_3720308, CV 4.2%, sensitivity 0.02 ng/mL), estradiol (Alpco Diagnostics catalog No. 11-ESTHU-E01, RRID:AB_2756385, CV 7.6%, sensitivity 10 pg/mL), insulin like growth factor-1 (IGF-1; Alpco Diagnostics catalog No. 22-IGFHU-E01, RRID:AB_2923276, 1:20 dilution, average CV 3.3%, assay sensitivity 9.4 pg/mL), IGF binding protein-5 (IGFBP-5; R and D Systems catalog No. DY875, RRID:AB_3720311, 3× dilution, CV 2.7%), parathyroid hormone (PTH; (Alpco Diagnostics catalog No. 21-IPTHU-E01, RRID:AB_2943035), CV 7.3%, sensitivity 1.6 pg/mL), and plasma β C-terminal cross-linked telopeptide of type I collagen (βCTX; Immunodiagnostic Systems catalog No. IS-3000N, RRID:AB_3720313, CV 6.2%, sensitivity 3.2 pmol/L).

Techniques: Biomarker Discovery, Control, Binding Assay